Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of ocaperidone in continuation treatment of schizophrenia
2004-003776-10Phase 2Completed
- Sponsor
- Neuro3d
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ocaperidone in schizophrenia (3 arms), sponsored by Neuro3d. Primary endpoints: Safety and tolerability and Body weight change. Started Jan 2005; status: completed.
02
Drugs
ocaperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-003776-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003776-10.